New Directions in Depression Treatment: Hopes, Challenges, and the Future of Integrated Psychiatry

Alfonsi, V., Scarpelli, S., D'Atri, A., Stella, G., & De Gennaro, L. (2020). Later school start time: The impact of sleep on academic performance and health in the adolescent population. International Journal of Environmental Research and Public Health, 17(7), 2574. https://doi.org/10.3390/ijerph17072574

American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., McEvoy, P., English, C., ... & Newby, J. M. (2018). Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: An updated meta-analysis. Journal of Anxiety Disorders, 55, 70–78. https://doi.org/10.1016/j.janxdis.2018.01.001

Baumel, A., Muench, F., Edan, S., & Kane, J. M. (2019). Objective User Engagement With Mental Health Apps: Systematic Search and Panel-Based Usage Analysis. Journal of Medical Internet Research, 21(9), e14567. https://doi.org/10.2196/14567

Cain, D. J. (2010). Person-Centered Psychotherapies. Washington, DC: American Psychological Association.

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., ... & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627. https://doi.org/10.1016/S2215-0366(16)30065-7

Carlbring, P., Andersson, G., Cuijpers, P., Riper, H., & Hedman-Lagerlöf, E. (2018). Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: An updated systematic review and meta-analysis. Cognitive Behaviour Therapy, 47(1), 1–18. https://doi.org/10.1080/16506073.2017.1401115

Cooper, M. (2009). Existential therapies: Contributions to a pluralistic practice. Journal of Contemporary Psychotherapy, 39(2), 103–115. https://doi.org/10.1007/s10879-008-9109-6

Cuijpers, P., Karyotaki, E., Reijnders, M., & Purgato, M. (2020). Meta-analyses and mega-analyses of the effectiveness of digital health interventions for mental health. World Psychiatry, 19(3), 337–338. https://doi.org/10.1002/wps.20784

Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., ... & Drevets, W. C. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression. JAMA Psychiatry, 76(9), 893–903. https://doi.org/10.1001/jamapsychiatry.2019.1189

Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285

Dimidjian, S., Barrera, M., Martell, C., Muñoz, R. F., & Lewinsohn, P. M. (2011). The origins and current status of behavioral activation treatments for depression. Annual Review of Clinical Psychology, 7, 1–38. https://doi.org/10.1146/annurev-clinpsy-032210-104535

Elliott, R., Watson, J., Greenberg, L. S., Timulak, L., & Freire, E. (2013). Research on humanistic–experiential psychotherapies. In M. J. Lambert (Ed.), Bergin and Garfield's handbook of psychotherapy and behavior change (6th ed., pp. 495–538). New York: Wiley.

Engel, G. L. (1980). The clinical application of the biopsychosocial model. The American Journal of Psychiatry, 137(5), 535–544. https://doi.org/10.1176/ajp.137.5.535

FDA. (2019). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. Retrieved from https://www.fda.gov

Firth, J., Solmi, M., Wootton, R. E., Vancampfort, D., Schuch, F. B., Hoare, E., ... & Stubbs, B. (2019). A meta-review of “lifestyle psychiatry”: The role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry, 18(3), 308–328. https://doi.org/10.1002/wps.20672

Fitzpatrick, K. K., Darcy, A., & Vierhile, M. (2017). Delivering Cognitive Behavior Therapy to Young Adults With Symptoms of Depression and Anxiety Using a Fully Automated Conversational Agent (Woebot): A Randomized Controlled Trial. JMIR Mental Health, 4(2), e19. https://doi.org/10.2196/mental.7785

Francesetti, G. (2013). Depression and the Body in Gestalt Therapy. Milano: FrancoAngeli.

Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U., & Jesse, R. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513

Inkster, B., Sarda, S., & Subramanian, V. (2018). An Empathy-Driven, Conversational Artificial Intelligence Agent (Wysa) for Digital Mental Well-Being: Real-World Data Evaluation Mixed-Methods Study. JMIR mHealth and uHealth, 6(11), e12106. https://doi.org/10.2196/12106

Insel, T. R. (2017). Digital phenotyping: Technology for a new science of behavior. JAMA, 318(13), 1215–1216. https://doi.org/10.1001/jama.2017.11295

Jacka, F. N., O’Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., ... & Berk, M. (2017). A randomised controlled trial of dietary improvement for adults with major depression (the “SMILES” trial). BMC Medicine, 15(1), 23. https://doi.org/10.1186/s12916-017-0791-y

Kendler, K. S. (2012). The dappled nature of causes of psychiatric illness: Replacing the organic–functional/hardware–software dichotomy with empirically based pluralism. Molecular Psychiatry, 17(4), 377–388. https://doi.org/10.1038/mp.2011.182

Miller, R. B., Wampold, B. E., & Varhely, K. (2017). The therapist factor: Implications for training and practice. Psychotherapy, 54(4), 369–375. https://doi.org/10.1037/pst0000121

Mohr, D. C., Weingardt, K. R., Reddy, M., & Schueller, S. M. (2017). Three problems with current digital mental health research... and three things we can do about it. Psychiatric Services, 68(5), 427–429. https://doi.org/10.1176/appi.ps.201600541

Norcross, J. C., & Goldfried, M. R. (2019). Handbook of psychotherapy integration (3rd ed.). New York: Oxford University Press.

Perls, F., Hefferline, R., & Goodman, P. (1951). Gestalt Therapy: Excitement and Growth in the Human Personality. New York: Julian Press.

Pincus, H. A., Pechura, C. M., Elinson, L., & Pettit, A. R. (2007). Depression in primary care: Linking clinical and systems strategies. General Hospital Psychiatry, 23(6), 311–318. https://doi.org/10.1016/S0163-8343(01)00157-1

Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., ... & Manji, H. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. American Journal of Psychiatry, 176(6), 428–438. https://doi.org/10.1176/appi.ajp.2019.19020172

Rush, A. J., Trivedi, M. H., Wisniewski, S. R., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905

Schuch, F. B., Vancampfort, D., Richards, J., Rosenbaum, S., Ward, P. B., & Stubbs, B. (2016). Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. Journal of Psychiatric Research, 77, 42–51. https://doi.org/10.1016/j.jpsychires.2016.02.023

Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018). Side-effects associated with ketamine use in depression: a systematic review. The Lancet Psychiatry, 5(1), 65–78. https://doi.org/10.1016/S2215-0366(17)30272-9

World Health Organization. (2019). International Classification of Diseases 10th Revision (ICD-10): Classification of Mental and Behavioural Disorders. Geneva: WHO.

World Health Organization. (2021). Depression. Retrieved from https://www.who.int/news-room/fact-sheets/detail/depression

World Health Organization. (2022). ICD-11 for Mortality and Morbidity Statistics: Mental, behavioural or neurodevelopmental disorders. Geneva: WHO.